theMednetRegister

Internal Medicine

NCI-CCC Tumor Board Question   

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?
AQUILA trial - NEJM
3 Answers available
For a patient with ENKTL nasal type (nose/sinus involvement) who has hepatic toxicity with pegasparaginase but a CR after 2 cycles of chemotherapy with a plan for "sandwich" radiotherapy - what, if any, chemotherapy would you resume after completion of radiation?
I am not sure there is much efficacy for a regimen that does not include asparaginase. The patient received 2 cycles of P-GemOx, then was admitted for...
2 Answers available
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
1 Answer available
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...
2 Answers available
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
7 Answers available
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
1 Answer available
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
1 Answer available
How would you treat a patient who received 2 cycles of R-CHOP for DLBCL who was subsequently diagnosed with follicular lymphoma?
Would you continue R-CHOP or would you switch therapy? 
1 Answer available
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?
1 Answer available
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
1 Answer available
How would you manage biopsy-proven DLBCL in a patient who was treated with 6 cycles of R-CHOP 15 years ago for DLBCL?
Would you consider this de novo DLBCL (unable to assess for clonality)? How would you handle prior anthracycline exposure? 
1 Answer available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
2 Answers available
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
2 Answers available
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
1 Answer available
How do you approach the initial dosing of carfilzomib for patients with relapsed multiple myeloma?
Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?
2 Answers available
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
1 Answer available
How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?
1 Answer available
How do you approach post-transplant maintenance for patients with high-risk myeloma?
Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...
2 Answers available
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
1 Answer available
How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?
240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...
2 Answers available
What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?
5 Answers available
What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?
Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...
1 Answer available
In light of the TRIANGLE data at ASH, how should we now approach a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?
2 Answers available
How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?
How do you choose between CAR-T and autoSCT, for example? 
3 Answers available
How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?
1 Answer available
How would you approach therapy for a transplant-eligible patient with peripheral T cell lymphoma NOS who experiences early relapse after CHOEP, but achieves remission to salvage therapy?
Would you still go to auto or consider allo? 
1 Answer available
How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?
Would you intercalate HD-MTX with her CHOEP?
1 Answer available
What is your preferred management for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)?
Does your management change if symptomatic or asymptomatic?
1 Answer available
What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?
1 Answer available
How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?
1 Answer available
How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?
1 Answer available
What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?
1 Answer available
How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?
1 Answer available
How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?
1 Answer available
How would you approach a patient with imaging and labs suggestive of potentially resectable cholangiocarcinoma when several core biopsies reveal bridging fibrosis with no malignant cells?
1 Answer available
In patients with HCC and asymptomatic but endoscopically visible varices, how long do you wait to start bevacizumab after banding?
1 Answer available
For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?
1 Answer available
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
2 Answers available
Which patients with smoldering myeloma do you treat?
2 Answers available
How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
2 Answers available
How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?
Ki67  = 90% with multiple small nodes on PET scan and normal CBC
1 Answer available
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
2 Answers available
What's the optimal management of stage IA nodal ATLL in a young fit patient?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
1 Answer available
What is your preferred maintenance strategy for high risk multiple myeloma?
2 Answers available
What is the role of liver transplant in NET?
3 Answers available
What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?
Would you try atezolizumab/bevacizumab or switch to a TKI?
2 Answers available
How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available
Are you routinely using thrombopoietin agonists in patients with hep C and HCC?
If so, for what platelet count threshold and do you have a preference as to which agent?
1 Answer available
How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?
1 Answer available


Papers discussed in this category

Journal of the National Cancer Institute, 2010-07-07
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
J Natl Cancer Inst, 2006 Jul 5
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
J. Natl. Cancer Inst., 2010-07-07
Tamoxifen and the factor V Leiden mutation.
J. Clin. Oncol., 2003-10-01
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.
Eur J Haematol, 2023 Mar 27
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Gastroenterology, 2018 May 17
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Clin. Gastroenterol. Hepatol., 2018 Nov 28
Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hepatology (Baltimore, Md.), 2019-10
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
The New England journal of medicine, 2018-07-05
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Lancet (London, England), 2018-03-24
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
J Gastroenterol, 2019 Nov 12
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Am Heart J, 2010 Sep 18
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
N Engl J Med,
Sorafenib in advanced hepatocellular carcinoma.
Lancet (London, England), 2017-01-07
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 2019-02
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
JAMA Oncol, 2020 Dec 10
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Hepatology, 2019 Oct 14
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Am J Transplant, 2016 Jun 09
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.
Transplantation, 2021 Apr 27
Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.
Surgery, 2017 Jun 16
Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.
The New England journal of medicine, 2012-05-10
Lenalidomide after stem-cell transplantation for multiple myeloma.
Nature communications, 2019-04-23
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Blood, 2012 Aug 13
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
J Clin Oncol, 2020 Apr 16
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Blood,
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
The Lancet. Oncology, 2019-01
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Blood,
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
The Lancet. Oncology, 2018-07
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Blood Cancer J, 2020 Mar 09
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
JAMA Oncol,
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Haematologica, 2021 Jun 01
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Outcome of deferred initial therapy in mantle-cell lymphoma.
The New England journal of medicine, 2015-11-05
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Haematologica, 2018 May 24
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.
Blood,
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Leukemia, 2011 Jul 01
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Haematologica, 2019 Sep 19
mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Blood, 2017 Aug 17
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood, 2015 May 28
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Blood Cancer J, 2021 Jan 11
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
N Engl J Med,
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Blood cancer journal, 2018-06-12
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
J. Clin. Oncol., 2019 Oct 25
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
JAMA Oncol,
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
British journal of haematology, 2014-06
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
International journal of radiation oncology, biology, physics, 2019-06-01
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Blood, 2018-07-05
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood,
Getting to transplant in Hodgkin lymphoma: BVB.
Blood,
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
British journal of haematology, 2017-11
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
J Clin Oncol, 2016 Feb 29
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Lancet Haematol, 2016 Dec 05
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Lancet Oncol, 2022 Jan 21
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
N Engl J Med,
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Lancet Haematol,
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Leukemia, 2020 Jul 21
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
J Clin Oncol, 2022 Dec 22
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Blood Adv, 2022 May 10
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Blood, 2022 Dec 15
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
Ann Oncol, 2009 Jul 01
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood, 2010 Jul 21
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Chest, 2020 Aug 14
Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Retrospective Analysis.
Chest, 2020 Jul
Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia.
ERJ Open Res, 2020 Oct
Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
Lancet (London, England), 2019-01-19
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
N Engl J Med, 2022 Jun 03
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
J Hematol Oncol, 2021 Oct 30
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Blood, 2022 Mar 03
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Lancet,
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
N Engl J Med, 2021 Dec 11
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Lancet Oncol, 2020 Jun 05
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol, 2022 Jul 12
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Blood, 2022 Oct 20
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
J Clin Oncol, 2017 Jan 17
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
The Lancet. Oncology, 2011 Dec 13
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
American journal of hematology, 2016-09
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Blood, 2017 Jun 13
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
Blood, 2020 Apr 09
Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.
Blood advances, 2023 Sep 26
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.
Kidney international, 2018-07
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.
BMC nephrology, 2019-02-14
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
Scientific reports, 2022 Nov 29
High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-10
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Blood, 2015 Jun 24
Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009 Oct 05
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
The New England journal of medicine, 2024 Dec 09
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Blood cancer journal, 2020 Oct 16
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Blood advances, 2023 Nov 14
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Related Topics in Internal Medicine

Copyright © 2025 theMednet
All Rights Reserved.